期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Controversy of the prostate-specific antigen test era： should prostate cancer be detected and treated in all patients？ 被引量：1

Controversy of the prostate-specific antigen test era： should prostate cancer be detected and treated in all patients？
原文传递
导出
摘要 The United States Food and Drug Administration approved the prostate-specific antigen （PSA） test in 1986 for monitoring the progression of prostate cancer; in 1994, the test was approved for the early detection of prostate cancer.1 The application of the PSA test has significantly increased the detection rate of prostate cancer. However, with the wider application of the PSA test, The United States Food and Drug Administration approved the prostate-specific antigen （PSA） test in 1986 for monitoring the progression of prostate cancer; in 1994, the test was approved for the early detection of prostate cancer.1 The application of the PSA test has significantly increased the detection rate of prostate cancer. However, with the wider application of the PSA test,
作者 ZHANG Ning ZHANG Xiao-dong
机构地区 Department of Urology
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第15期2803-2804,共2页 中华医学杂志（英文版）
关键词 prostate-specific antigen ＂ screen prostate-specific antigen,＂ screen
分类号 S858.315.3 [农业科学—临床兽医学] Q78 [生物学—分子生物学]
  • 相关文献

参考文献12

  • 1Stark JR, Mucci L, Rothman KJ, Adami RO. Screening for prostate cancer remains controversial. BMJ 2009; 24; 339: b3601.
  • 2Thompson 1M, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes RL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level (4.0 ng per milliliter). N Engl J Med 2004; 350: 2239-2246.
  • 3Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2011; 61: 133-134.
  • 4lie D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013; 31: 1.
  • 5Schroder FR, Gosselaar C, Roemeling S, Postma R, Roobol MJ, Bangma CR. PSA and the detection of prostate cancer after 2005. Part 1. EAU-EBU Update Series 2006; 4: 2-12.
  • 6Montironi R, Mazzucchelli R, Santinelli A, Scarpelli M, Beltran AL, Bostwick DG. Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens. Rum Patho12005; 36: 646-654.
  • 7Van der Kwast TR, Roobol MJ. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 2013; 28: Epub ahead of print.
  • 8Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Uro12004; 172: 1297-1301.
  • 9Schroder FR, Carter RB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CR, et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008; 53: 468-477.
  • 10Schroder FR, Gosselaar C, Roemeling S, Postma R, Roobol MJ, Bangma CR. PSA and the detection of prostate cancer after 2005. Part II: Ways out of the PSA dilemma? EAU-EBU Update Series 2006; 4: 71-81.

同被引文献3

引证文献1

二级引证文献11

Chinese Medical Journal
2013年 第15期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部